Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biochem Biophys Res Commun ; 500(2): 435-442, 2018 06 02.
Artículo en Inglés | MEDLINE | ID: mdl-29660334

RESUMEN

BACKGROUND: Effects of lutein (L) and fatty acids [linoleic acid (LA), eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) and oleic acid (OA)] on oxidative stress and inflammation in cataract were assessed. METHODS: Cataract was induced in male Wistar rat pups (11 days old) by giving a single dose of sodium selenite (25 µM/kg body weight) by IP. Lutein (1.3 µmol/kg body weight) was given one day before and five days after selenite injection as a micelle with 7.5 mM LA, or 7.5 mM EPA + DHA or 7.5 mM OA. Serum and lens oxidative stress and inflammatory parameters having a bearing cataract were assessed. RESULTS: Serum and lens nitric oxide, MDA and protein carbonyls were significantly (p < 0.05) increased in cataract compared to control and experimental groups. Catalase, SOD, glutathione peroxidase and glutathione transferase activity and glutathione level in serum and lens of cataract group were significantly (p < 0.05) decreased. Serum eicosanoids (PGE2, LTB4, and LTC4) and cytokines (CRP, TNF-α, IL1-ß, and MCP-1) were significantly (p < 0.05) increased in cataract. The activity of cPLA2 and Cox-2 in cataract lens was higher (p < 0.05) compared to other groups. EP-1, NOS-2 and NF-kB expression were higher (p < 0.05) in cataract. The ratio of water insoluble to water soluble protein was increased in cataract lens. Group administered with L + EPA + DHA exhibited highest cataract prevention compared to L + LA and L + OA. Pups given lutein with EPA + DHA had the highest amount of lutein in the lens. CONCLUSIONS: The anti-cataract activity of lutein was influenced by fatty acids and found to be highest with EPA + DHA compared to LA or OA.


Asunto(s)
Catarata/tratamiento farmacológico , Catarata/prevención & control , Ácidos Grasos/uso terapéutico , Inflamación/tratamiento farmacológico , Luteína/uso terapéutico , Estrés Oxidativo , Animales , Antioxidantes/metabolismo , Biomarcadores/sangre , Catarata/sangre , Ciclooxigenasa 2/metabolismo , Citocinas/sangre , Eicosanoides/sangre , Proteínas del Ojo/metabolismo , Ácidos Grasos/farmacología , Glutatión/sangre , Glutatión/metabolismo , Inflamación/patología , Cristalino/metabolismo , Cristalino/patología , Luteína/farmacología , Masculino , Modelos Biológicos , FN-kappa B/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Estrés Oxidativo/efectos de los fármacos , Fosfolipasas A2 Citosólicas/metabolismo , Ratas , Subtipo EP1 de Receptores de Prostaglandina E/metabolismo , Solubilidad , Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA